BRPI0917411A2 - composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit. - Google Patents

composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.

Info

Publication number
BRPI0917411A2
BRPI0917411A2 BRPI0917411A BRPI0917411A BRPI0917411A2 BR PI0917411 A2 BRPI0917411 A2 BR PI0917411A2 BR PI0917411 A BRPI0917411 A BR PI0917411A BR PI0917411 A BRPI0917411 A BR PI0917411A BR PI0917411 A2 BRPI0917411 A2 BR PI0917411A2
Authority
BR
Brazil
Prior art keywords
cell
subject
rassf1a
cells
dansyl
Prior art date
Application number
BRPI0917411A
Other languages
English (en)
Portuguese (pt)
Inventor
Kathryn D Sheikh
Mikell Paige
Milton L Brown
Partha Banerjee
Shankar Jagadeesh
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of BRPI0917411A2 publication Critical patent/BRPI0917411A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0917411A 2008-08-15 2009-08-14 composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit. BRPI0917411A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18905908P 2008-08-15 2008-08-15
PCT/US2009/004681 WO2010019271A1 (en) 2008-08-15 2009-08-14 Fluorescent regulators of rassf1a expression and human cancer cell proliferation

Publications (1)

Publication Number Publication Date
BRPI0917411A2 true BRPI0917411A2 (pt) 2015-12-01

Family

ID=41279343

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917411A BRPI0917411A2 (pt) 2008-08-15 2009-08-14 composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.

Country Status (9)

Country Link
US (1) US10457639B2 (OSRAM)
EP (2) EP2323982B1 (OSRAM)
JP (2) JP2012500197A (OSRAM)
CN (1) CN102186820B (OSRAM)
AT (1) ATE547403T1 (OSRAM)
AU (1) AU2009282451B2 (OSRAM)
BR (1) BRPI0917411A2 (OSRAM)
CA (1) CA2734225A1 (OSRAM)
WO (1) WO2010019271A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
SG183407A1 (en) 2010-03-08 2012-09-27 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
US8637679B2 (en) 2011-03-11 2014-01-28 Council Of Scientific And Industrial Research Process for the isolation of organic compounds useful for the treatment of cancer
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
CA2848680C (en) 2011-09-13 2020-05-19 Monsanto Technology Llc Methods and compositions for weed control
MX348495B (es) 2011-09-13 2017-06-14 Monsanto Technology Llc Metodos y composiciones para el control de malezas.
AU2012308686B2 (en) 2011-09-13 2018-05-10 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
CA2848695A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and composition for weed control comprising inhibiting ppg oxidase
AU2012308694B2 (en) 2011-09-13 2018-06-14 Monsanto Technology Llc Methods and compositions for weed control
CA2873828A1 (en) 2012-05-24 2013-11-28 A.B. Seeds Ltd. Naked dsrna for silencing target molecules in plant seeds
EP2941487A2 (en) 2013-01-01 2015-11-11 A.B. Seeds Ltd. ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
CN105074008A (zh) 2013-03-13 2015-11-18 孟山都技术有限公司 用于杂草控制的方法和组合物
CN105263329B (zh) 2013-03-13 2020-09-18 孟山都技术公司 用于杂草控制的方法和组合物
WO2014151317A1 (en) * 2013-03-15 2014-09-25 Rush University Medical Center Methods for treating cancer
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
UA122662C2 (uk) 2013-07-19 2020-12-28 Монсанто Текнолоджі Ллс Композиція та спосіб боротьби з leptinotarsa
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
RU2694950C2 (ru) 2013-11-04 2019-07-18 Монсанто Текнолоджи Ллс Композиции и способы для борьбы с членистоногими паразитами и заражениями вредителями
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
WO2015108982A2 (en) 2014-01-15 2015-07-23 Monsanto Technology Llc Methods and compositions for weed control using epsps polynucleotides
CN106413390B (zh) 2014-04-01 2019-09-27 孟山都技术公司 用于控制虫害的组合物和方法
CA2953347A1 (en) 2014-06-23 2015-12-30 Monsanto Technology Llc Compositions and methods for regulating gene expression via rna interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
RU2021123470A (ru) 2014-07-29 2021-09-06 Монсанто Текнолоджи Ллс Композиции и способы борьбы с насекомыми-вредителями
JP6942632B2 (ja) 2015-01-22 2021-09-29 モンサント テクノロジー エルエルシー Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
UY36703A (es) 2015-06-02 2016-12-30 Monsanto Technology Llc Composiciones y métodos para la administración de un polinucleótido en una planta
WO2016196782A1 (en) 2015-06-03 2016-12-08 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
WO2017023916A1 (en) * 2015-08-05 2017-02-09 Georgetown University Small molecule androgen receptor inhibitors and methods of use thereof
CN110785166A (zh) * 2017-06-12 2020-02-11 宫田升平 抗癌药及其用途
CN107266356B (zh) * 2017-07-25 2020-06-26 山西省生物研究院有限公司 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2235815A1 (de) * 1972-07-21 1974-01-31 Bayer Ag Polyazofarbstoffe
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
GB9215361D0 (en) 1992-07-20 1992-09-02 Wellcome Found Heterocyclic compounds
JP3690825B2 (ja) * 1993-07-26 2005-08-31 エーザイ株式会社 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体
ATE225334T1 (de) * 1993-07-26 2002-10-15 Eisai Co Ltd Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring
CA2186412A1 (en) * 1995-10-31 1997-05-01 Katherine S. Takaki Ethylamino carbazole melatonergic agents
DE69830513T2 (de) * 1997-12-22 2006-03-16 Bayer Pharmaceuticals Corp., West Haven HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
US6713473B1 (en) * 1999-04-20 2004-03-30 Meiji Seika Kaisha, Ltd. Tricyclic compounds
WO2001044187A1 (en) 1999-12-16 2001-06-21 Asahi Kasei Kabushiki Kaisha Novel substituted tricyclic compounds
AU2001252575A1 (en) 2000-04-28 2001-11-12 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
UA82827C2 (en) * 2000-12-18 2008-05-26 Inhibitors against the production and release of inflammatory cytokines
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
WO2002074306A1 (en) 2001-03-19 2002-09-26 Asahi Kasei Kabushiki Kaisha Remedies for fatty liver
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
WO2006002908A1 (en) 2004-06-29 2006-01-12 Jadolabs Gmbh Carbazole-derived pharmaceutical compositions
CN101014569B (zh) 2004-08-18 2013-01-02 西巴特殊化学品控股有限公司 肟酯光引发剂
ITMI20051523A1 (it) 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
CN101252945A (zh) 2005-09-01 2008-08-27 科学与工业研究会 一种用于治疗前列腺癌的药物组合物
CN1807413B (zh) 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
WO2007042912A2 (en) * 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pstat3/il-6 inhibitors
US20100130579A1 (en) * 2006-10-23 2010-05-27 Georgetown University Cancer therapy
IL186935A0 (en) 2006-10-31 2008-02-09 Veridex Llc Prostate cancer field effect analysis methods and kits
EP2238265A4 (en) 2007-12-28 2012-01-18 Wayne John Cancer Inst USE OF THE METHYLATION STATE OF MINT-LOCI AND TUMOR ASSOCIATED GENES AS A MARKER FOR MELANOMA AND MAMMARIAN CARCINOMA
ES2524259T3 (es) 2008-03-24 2014-12-04 Novartis Ag Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida

Also Published As

Publication number Publication date
CA2734225A1 (en) 2010-02-18
HK1158206A1 (en) 2012-07-13
JP2012500197A (ja) 2012-01-05
US20110152339A1 (en) 2011-06-23
CN102186820B (zh) 2013-08-28
EP2484666A1 (en) 2012-08-08
US10457639B2 (en) 2019-10-29
JP2014148545A (ja) 2014-08-21
EP2323982B1 (en) 2012-02-29
CN102186820A (zh) 2011-09-14
EP2323982A1 (en) 2011-05-25
WO2010019271A8 (en) 2011-03-31
AU2009282451B2 (en) 2014-02-13
ATE547403T1 (de) 2012-03-15
WO2010019271A1 (en) 2010-02-18
AU2009282451A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
BRPI0917411A2 (pt) composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.
Zhou et al. Inorganic–organic hybrid nanoprobe for NIR‐excited imaging of hydrogen sulfide in cell cultures and inflammation in a mouse model
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
EA201101585A1 (ru) 3-(1,2,3-триазол-4-ил)пирроло[2,3-b]пиридинпроизводные
ATE513832T1 (de) 8-anilinoimidazopyridine und ihre verwendung als antikrebsmittel und/oder entzündungshemmende mittel
EA201290389A8 (ru) Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
MX2010003368A (es) Derivados de imidazol.
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
EA200970108A1 (ru) Композиции и способы для ингибирования роста smad4-дефицитных форм рака
ATE541053T1 (de) Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs
WO2006135886A3 (en) Compositions and methods for treating and diagnosing cancer
ECSP088598A (es) Derivados de piridazinona
ZA200701137B (en) Triazolophthalazines
RU2011143520A (ru) Способы и композиции для лечения злокачественных опухолей
BRPI0518198B8 (pt) método ex vivo para tratar uma composição de células hemácias para inativar um patógeno, se presente, bem como composição e kit
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
WO2009153774A3 (en) Compositions and methods for prognosis of ovarian cancer
BRPI0511138A (pt) derivados de pirimidina para o tratamento de desenvolvimento celular anormal
ATE487721T1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
BR0303012A (pt) Avaliação de câncer colorretal
BR0303091A (pt) Avaliação de câncer colorretal
Qi et al. Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]